Central Nervous System Symptoms: Headache, Seizures, Encephalopathy, and Memory Impairment

  • Roxana S. Dronca
  • Charles L. Loprinzi
  • Daniel H. Lachance


Involvement of the central nervous system (CNS) represents a common cause of morbidity and mortality in patients with cancer. The clinical manifestations are pleomorphic, ranging from headache, seizures, acute mental status changes, focal neurological deficits, or chronic cognitive and memory changes. In patients with known and treated tumors, careful analysis of the clinical symptoms may help distinguish between neurologic complications of therapy from those due to cancer itself, paraneoplastic syndromes, toxic or metabolic derangements. Palliation of symptoms using a multimodality therapy approach may be necessary when symptoms are not relieved by the treatment of the underlying tumor.


Primary Central Nervous System Lymphoma Posterior Reversible Encephalopathy Syndrome Focal Neurological Deficit Metastatic Brain Tumor Reversible Posterior Leukoencephalopathy Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    The Childhood Brain Tumor Consortium. The epidemiology of headache among children with brain tumor. Headache in children with brain tumors. J Neurooncol 1991;10(1):31–46.Google Scholar
  2. 2.
    Forsyth PA, Posner JB. Headaches in patients with brain tumors: a study of 111 patients. Neurology 1993;43(9):1678–83.PubMedCrossRefGoogle Scholar
  3. 3.
    Lowry JK, Snyder JJ, Lowry PW. Brain tumors in the elderly: recent trends in a Minnesota cohort study. Arch Neurol 1998;55(7): 922–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Christiaans MH, Kelder JC, Arnoldus EP, Tijssen CC. Prediction of intracranial metastases in cancer patients with headache. Cancer 2002;94(7):2063–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Pfund Z, Szapary L, Jaszberenyi O, Nagy F, Czopf J. Headache in intracranial tumors. Cephalalgia 1999;19(9):787–90; discussion 65.Google Scholar
  6. 6.
    DeAngelis LM, Boutros D. Leptomeningeal metastasis. Cancer Invest 2005;23(2):145–54.PubMedCrossRefGoogle Scholar
  7. 7.
    Greenberg HS, Deck MD, Vikram B, Chu FC, Posner JB. Metastasis to the base of the skull: clinical findings in 43 patients. Neurology 1981;31(5):530–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Abraham PJ, Capobianco DJ, Cheshire WP. Facial pain as the presenting symptom of lung carcinoma with normal chest radiograph. Headache 2003;43(5):499–504.PubMedCrossRefGoogle Scholar
  9. 9.
    Kaur A, Selwa L, Fromes G, Ross DA. Persistent headache after supratentorial craniotomy. Neurosurgery 2000;47(3):633–6.PubMedGoogle Scholar
  10. 10.
    Geiser CF, Bishop Y, Jaffe N, Furman L, Traggis D, Frei E, 3rd. Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. Blood 1975;45(2):189–95.PubMedGoogle Scholar
  11. 11.
    Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999;17(10):3110–6.PubMedGoogle Scholar
  12. 12.
    Bleyer AW. Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. Cancer Treat Rep 1977;61(8):1419–25.PubMedGoogle Scholar
  13. 13.
    Pochedly C. Prevention of meningeal leukemia. Review of 20 years of research and current recommendations. Hematol Oncol Clin North Am 1990;4(5):951–69.PubMedGoogle Scholar
  14. 14.
    Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334(8): 494–500.PubMedCrossRefGoogle Scholar
  15. 15.
    Young DF, Posner JB, Chu F, Nisce L. Rapid-course radiation therapy of cerebral metastases: results and complications. Cancer 1974;34(4):1069–76.PubMedCrossRefGoogle Scholar
  16. 16.
    Sorensen JB, Andersen MK, Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med 1995;238(2):97–110.PubMedCrossRefGoogle Scholar
  17. 17.
    Schachter SC. Iatrogenic seizures. Neurol Clin 1998;16(1): 157–70.PubMedCrossRefGoogle Scholar
  18. 18.
    Lote K, Stenwig AE, Skullerud K, Hirschberg H. Prevalence and prognostic significance of epilepsy in patients with gliomas. Eur J Cancer 1998;34(1):98–102.PubMedCrossRefGoogle Scholar
  19. 19.
    Cohen N, Strauss G, Lew R, Silver D, Recht L. Should prophylactic anticonvulsants be administered to patients with newly-diagnosed cerebral metastases? A retrospective analysis. J Clin Oncol 1988;6(10):1621–4.PubMedGoogle Scholar
  20. 20.
    Cavaliere R, Farace E, Schiff D. Clinical implications of status epilepticus in patients with neoplasms. Arch Neurol 2006;63(12): 1746–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Messing RO, Closson RG, Simon RP. Drug-induced seizures: a 10-year experience. Neurology 1984;34(12):1582–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Lim DA, Tarapore P, Chang E, et al. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. J Neurooncol 2009;93(3):349–54.PubMedCrossRefGoogle Scholar
  23. 23.
    Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;54(10):1886-93.PubMedCrossRefGoogle Scholar
  24. 24.
    Sirven JI, Wingerchuk DM, Drazkowski JF, Lyons MK, Zimmerman RS. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc 2004;79(12):1489–94.PubMedCrossRefGoogle Scholar
  25. 25.
    Tremont-Lukats IW, Ratilal BO, Armstrong T, Gilbert MR. Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev 2008(2):CD004424.PubMedGoogle Scholar
  26. 26.
    Graus F, Rogers LR, Posner JB. Cerebrovascular complications in patients with cancer. Medicine (Baltimore) 1985;64(1):16–35.Google Scholar
  27. 27.
    Rubnitz JE, Relling MV, Harrison PL, et al. Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. Leukemia 1998;12(8):1176–81.PubMedCrossRefGoogle Scholar
  28. 28.
    Walker RW, Allen JC, Rosen G, Caparros B. Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 1986;4(12):1845–50.PubMedGoogle Scholar
  29. 29.
    Phillips PC, Thaler HT, Berger CA, et al. Acute high-dose methotrexate neurotoxicity in the rat. Ann Neurol 1986;20(5):583–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Komatsu K, Takada G, Uemura K, Shishido F, Kanno I. Decrease in cerebral metabolic rate of glucose after high-dose methotrexate in childhood acute lymphocytic leukemia. Pediatr Neurol 1990;6(5): 303–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Phillips PC, Thaler HT, Allen JC, Rottenberg DA. High-dose leucovorin reverses acute high-dose methotrexate neurotoxicity in the rat. Ann Neurol 1989;25(4):365–72.PubMedCrossRefGoogle Scholar
  32. 32.
    David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol 2005;28(3): 277–80.PubMedCrossRefGoogle Scholar
  33. 33.
    Pratt CB, Green AA, Horowitz ME, et al. Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol 1986;4(8):1253–61.PubMedGoogle Scholar
  34. 34.
    Turner AR, Duong CD, Good DJ. Methylene blue for the treatment and prophylaxis of ifosfamide-induced encephalopathy. Clin Oncol (R Coll Radiol) 2003;15(7):435–9.CrossRefGoogle Scholar
  35. 35.
    Meanwell CA, Blake AE, Kelly KA, Honigsberger L, Blackledge G. Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol 1986;22(7):815–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Pratt CB, Goren MP, Meyer WH, Singh B, Dodge RK. Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors. J Clin Oncol 1990;8(8):1399–401.PubMedGoogle Scholar
  37. 37.
    Patel PN. Methylene blue for management of Ifosfamide-induced encephalopathy. Ann Pharmacother 2006;40(2):299–303.PubMedCrossRefGoogle Scholar
  38. 38.
    Zulian GB, Tullen E, Maton B. Methylene blue for ifosfamide-associated encephalopathy. N Engl J Med 1995;332(18):1239–40.PubMedCrossRefGoogle Scholar
  39. 39.
    Hamadani M, Awan F. Role of thiamine in managing ifosfamide-induced encephalopathy. J Oncol Pharm Pract 2006;12(4):237–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Liaw CC, Liaw SJ, Wang CH, Chiu MC, Huang JS. Transient hyperammonemia related to chemotherapy with continuous infusion of high-dose 5-fluorouracil. Anticancer Drugs 1993;4(3): 311–5.PubMedCrossRefGoogle Scholar
  41. 41.
    Nott L, Price TJ, Pittman K, Patterson K, Fletcher J. Hypera­mmonemia encephalopathy: an important cause of neurological deterioration following chemotherapy. Leuk Lymphoma 2007;48(9):1702–11.PubMedCrossRefGoogle Scholar
  42. 42.
    Liaw CC, Wang HM, Wang CH, et al. Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection. Anticancer Drugs 1999;10(3):275–81.PubMedCrossRefGoogle Scholar
  43. 43.
    Hook CC, Kimmel DW, Kvols LK, et al. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol 1992;31(3):262–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Israel ZH, Lossos A, Barak V, Soffer D, Siegal T. Multifocal demyelinative leukoencephalopathy associated with 5-fluorouracil and levamisole. Acta Oncol 2000;39(1):117–20.PubMedCrossRefGoogle Scholar
  45. 45.
    Stevenson HC, Green I, Hamilton JM, Calabro BA, Parkinson DR. Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer. J Clin Oncol 1991;9(11):2052–66.PubMedGoogle Scholar
  46. 46.
    Holland J, Fasanello S, Onuma T. Psychiatric symptoms associated with L-asparaginase administration. J Psychiatr Res 1974;10(2):105–13.PubMedCrossRefGoogle Scholar
  47. 47.
    Martin J, Mainwaring D. Letter: Coma and convulsions associated with vincristine therapy. Br Med J 1973;4(5895):782–3.PubMedCrossRefGoogle Scholar
  48. 48.
    Cheson BD, Vena DA, Foss FM, Sorensen JM. Neurotoxicity of purine analogs: a review. J Clin Oncol 1994;12(10):2216–28.PubMedGoogle Scholar
  49. 49.
    Perry JR, Warner E. Transient encephalopathy after paclitaxel (Taxol) infusion. Neurology 1996;46(6):1596–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Nieto Y, Cagnoni PJ, Bearman SI, et al. Acute encephalopathy: a new toxicity associated with high-dose paclitaxel. Clin Cancer Res 1999;5(3):501–6.PubMedGoogle Scholar
  51. 51.
    Denicoff KD, Rubinow DR, Papa MZ, et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1987;107(3):293–300.PubMedGoogle Scholar
  52. 52.
    Bernard JT, Ameriso S, Kempf RA, Rosen P, Mitchell MS, Fisher M. Transient focal neurologic deficits complicating interleukin-2 therapy. Neurology 1990;40(1):154–5.PubMedCrossRefGoogle Scholar
  53. 53.
    Somers SS, Reynolds JV, Guillou PJ. Multifocal neurotoxicity during interleukin-2 therapy for malignant melanoma. Clin Oncol (R Coll Radiol) 1992;4(2):135–6.CrossRefGoogle Scholar
  54. 54.
    Vecht CJ, Keohane C, Menon RS, Punt CJ, Stoter G. Acute fatal leukoencephalopathy after interleukin-2 therapy. N Engl J Med 1990;323(16):1146–7.PubMedGoogle Scholar
  55. 55.
    Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991;41(5):672–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Murray DM, Hensey OJ, O’Dwyer TP, King MD. Further evidence of neurological sequelae associated with interferon therapy in the paediatric population. Eur J Paediatr Neurol 2000;4(6):295–6.PubMedCrossRefGoogle Scholar
  57. 57.
    Schwartz RB, Bravo SM, Klufas RA, et al. Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. AJR Am J Roentgenol 1995;165(3): 627–31.PubMedGoogle Scholar
  58. 58.
    Bodkin CL, Eidelman BH. Sirolimus-induced posterior reversible encephalopathy. Neurology 2007;68(23):2039–40.PubMedCrossRefGoogle Scholar
  59. 59.
    Saito B, Nakamaki T, Nakashima H, et al. Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia. Am J Hematol 2007;82(4):304–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Ito Y, Arahata Y, Goto Y, et al. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol 1998;19(3):415–7.PubMedGoogle Scholar
  61. 61.
    Rajasekhar A, George TJ, Jr. Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature. Oncologist 2007;12(11):1332–5.PubMedCrossRefGoogle Scholar
  62. 62.
    Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006;354(9):980–2; discussion -2.Google Scholar
  63. 63.
    Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol 2008;65(2):205–10.PubMedCrossRefGoogle Scholar
  64. 64.
    Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol 2002;23(6): 1038–48.PubMedGoogle Scholar
  65. 65.
    Roth C, Ferbert A. Posterior Reversible Encephalopathy Syndrome – Long-term follow-up. J Neurol Neurosurg Psychiatry 2009.Google Scholar
  66. 66.
    Soussain C, Ricard D, Fike JR, Mazeron JJ, Psimaras D, Delattre JY. CNS complications of radiotherapy and chemotherapy. Lancet 2009;374(9701):1639–51.PubMedCrossRefGoogle Scholar
  67. 67.
    Hill JM, Kornblith AB, Jones D, et al. A comparative study of the long term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation. Cancer 1998;82(1):208–18.PubMedCrossRefGoogle Scholar
  68. 68.
    Hindo WA, DeTrana FA, 3rd, Lee MS, Hendrickson FR. Large dose increment irradiation in treatment of cerebral metastases. Cancer 1970;26(1):138–41.PubMedCrossRefGoogle Scholar
  69. 69.
    Evans ML, Graham MM, Mahler PA, Rasey JS. Use of steroids to suppress vascular response to radiation. Int J Radiat Oncol Biol Phys 1987;13(4):563–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Mandell LR, Walker RW, Steinherz P, Fuks Z. Reduced incidence of the somnolence syndrome in leukemic children with steroid coverage during prophylactic cranial radiation therapy. Results of a pilot study. Cancer 1989;63(10):1975–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Uzal D, Ozyar E, Hayran M, Zorlu F, Atahan L, Yetkin S. Reduced incidence of the somnolence syndrome after prophylactic cranial irradiation in children with acute lymphoblastic leukemia. Radiother Oncol 1998;48(1):29–32.PubMedCrossRefGoogle Scholar
  72. 72.
    Vern TZ, Salvi S. Somnolence syndrome and fever in pediatric patients with cranial irradiation. J Pediatr Hematol Oncol 2009;31(2):118–20.PubMedCrossRefGoogle Scholar
  73. 73.
    Faithfull S, Brada M. Somnolence syndrome in adults following cranial irradiation for primary brain tumours. Clin Oncol (R Coll Radiol) 1998;10(4):250–4.CrossRefGoogle Scholar
  74. 74.
    Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008;9(5):453–61.PubMedCrossRefGoogle Scholar
  75. 75.
    Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007;82(1):81–3.PubMedCrossRefGoogle Scholar
  76. 76.
    Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008;113(2): 405–10.PubMedCrossRefGoogle Scholar
  77. 77.
    Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008;26(13):2192–7.PubMedCrossRefGoogle Scholar
  78. 78.
    Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 2008;19(4):623–9.PubMedCrossRefGoogle Scholar
  79. 79.
    Tannock IF, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004;22(11):2233–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 2004;100(11):2292–9.PubMedCrossRefGoogle Scholar
  81. 81.
    Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, van Dam FS. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 2006;98(23):1742–5.PubMedCrossRefGoogle Scholar
  82. 82.
    van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998;90(3):210–8.PubMedCrossRefGoogle Scholar
  83. 83.
    Inagaki M, Yoshikawa E, Matsuoka Y, et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 2007;109(1): 146–56.PubMedCrossRefGoogle Scholar
  84. 84.
    Stemmer SM, Stears JC, Burton BS, Jones RB, Simon JH. White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. AJNR Am J Neuroradiol 1994;15(7):1267–73.PubMedGoogle Scholar
  85. 85.
    Carey ME, Haut MW, Reminger SL, Hutter JJ, Theilmann R, Kaemingk KL. Reduced frontal white matter volume in long-term childhood leukemia survivors: a voxel-based morphometry study. AJNR Am J Neuroradiol 2008;29(4):792–7.PubMedCrossRefGoogle Scholar
  86. 86.
    Silverman DH, Dy CJ, Castellon SA, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat 2007;103(3):303–11.PubMedCrossRefGoogle Scholar
  87. 87.
    Ochs J, Mulhern R, Fairclough D, et al. Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: a prospective study. J Clin Oncol 1991; 9(1):145–51.PubMedGoogle Scholar
  88. 88.
    Bleyer WA. Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat Rep 1981;65 Suppl 1:89–98.PubMedGoogle Scholar
  89. 89.
    Gangji D, Reaman GH, Cohen SR, Bleyer WA, Poplack DG. Leukoencephalopathy and elevated levels of myelin basic protein in the cerebrospinal fluid of patients with acute lymphoblastic leukemia. N Engl J Med 1980;303(1):19–21.PubMedCrossRefGoogle Scholar
  90. 90.
    Iuvone L, Mariotti P, Colosimo C, Guzzetta F, Ruggiero A, Riccardi R. Long-term cognitive outcome, brain computed tomography scan, and magnetic resonance imaging in children cured for acute lymphoblastic leukemia. Cancer 2002;95(12):2562–70.PubMedCrossRefGoogle Scholar
  91. 91.
    Blay JY, Conroy T, Chevreau C, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998;16(3):864–71.PubMedGoogle Scholar
  92. 92.
    Price RA, Jamieson PA. The central nervous system in childhood leukemia. II. Subacute leukoencephalopathy. Cancer 1975;35(2): 306–18.PubMedCrossRefGoogle Scholar
  93. 93.
    Liu HM, Maurer HS, Vongsvivut S, Conway JJ. Methotrexate encephalopathy. A neuropathologic study. Hum Pathol 1978;9(6): 635–48.PubMedCrossRefGoogle Scholar
  94. 94.
    Kapp JP, Sanford RA. Neurological deficit after carotid infusion of cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for malignant glioma: an analysis of risk factors. Neurosurgery 1986; 19(5):779–83.PubMedCrossRefGoogle Scholar

Copyright information

© Society for Imaging Informatics in Medicine 2010

Authors and Affiliations

  • Roxana S. Dronca
    • 1
  • Charles L. Loprinzi
  • Daniel H. Lachance
  1. 1.Department of Oncology/HematologyMayo ClinicRochesterUSA

Personalised recommendations